Gabapentin
Product Images NDC 68788-7119

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules Usp 400mg (civ)

Gabapentin Capsules USP 400mg label from Preferred Pharmaceuticals Inc. The label indicates the generic name, dosage strength of 400 mg per capsule, and shows manufacturer as Ascend Laboratories, LLC. It includes storage instructions, capsule color description, and bilingual dosing directions space in English and Spanish. The label features a barcode and a QR code.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients. The formula includes age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for females.*

FDA Label Image

Gabapentin Fig1

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis presents mean pain scores from 0 to 10, showing a decrease in pain scores for the Gabapentin group compared to placebo.*

FDA Label Image

Gabapentin Fig2

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks (baseline to week 7) and the y-axis represents mean pain score. The graph differentiates a 3-week dose titration period and a 4-week fixed dose period, illustrating decreases in pain scores for both Gabapentin dosages compared to placebo.*

FDA Label Image

Gabapentin Fig3

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) with Gabapentin (GBP) at various doses. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is noted with p-values <0.01 and <0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A bar chart depicting percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis for Gabapentin. Data points compare differences at doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg across three separate studies labeled Study a, Study b, and Study c, represented by distinct shaded squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.